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Abstract
Aerobic glycolysis is an important feature of cancer cells. In recent years, lactate dehydrogenase A (LDH-A) is emerging as a
novel therapeutic target for cancer treatment. Seeking LDH-A inhibitors from natural resources has been paid much
attention for drug discovery. Spatholobus suberectus (SS) is a common herbal medicine used in China for treating blood-
stasis related diseases such as cancer. This study aims to explore the potential medicinal application of SS for LDH-A
inhibition on breast cancer and to determine its bioactive compounds. We found that SS manifested apoptosis-inducing,
cell cycle arresting and anti-LDH-A activities in both estrogen-dependent human MCF-7 cells and estrogen-independent
MDA-MB-231 cell. Oral herbal extracts (1 g/kg/d) administration attenuated tumor growth and LDH-A expression in both
breast cancer xenografts. Bioactivity-guided fractionation finally identified epigallocatechin as a key compound in SS
inhibiting LDH-A activity. Further studies revealed that LDH-A plays a critical role in mediating the apoptosis-induction
effects of epigallocatechin. The inhibited LDH-A activities by epigallocatechin is attributed to disassociation of Hsp90 from
HIF-1a and subsequent accelerated HIF-1a proteasome degradation. In vivo study also demonstrated that epigallocatechin
could significantly inhibit breast cancer growth, HIF-1a/LDH-A expression and trigger apoptosis without bringing toxic
effects. The preclinical study thus suggests that the potential medicinal application of SS for inhibiting cancer LDH-A activity
and the possibility to consider epigallocatechin as a lead compound to develop LDH-A inhibitors. Future studies of SS for
chemoprevention or chemosensitization against breast cancer are thus warranted.
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Introduction
Cancer cells can be distinguished from normal cells in several
hallmarks including sustaining proliferative signaling, avoiding
immune destruction, resisting cell death, genome instability and
disordering angiogenesis, etc [1]. One of the hallmarks is that
cancer cells have a fundamentally different bioenergetic metabo-
lism from that of non-neoplastic cells [2,3]. In normal cells,
energetic metabolism mainly relies upon the mitochondrial
oxidative phosphorylation. In contrast, due to the hypoxia
microenvironment and mitochondrial gene mutations, cancer
cells have developed altered metabolism that predominantly
produce energy by glycolysis, even in the presence of oxygen -
this is known as the ‘‘Warburg Effect’’ [4]. Cancer glycolysis is a
critical step in carcinogenesis and oncogenic activation. Targeting
on glycolysis pathway has already become an important strategy
for cancer diagnosis and treatment in clinic [5].
The glycolysis pathway is a series of metabolic reactions
catalyzed by multiple enzymes or enzyme complexes. From the
original glucose uptake to the final lactate production, the key
steps involved in the process include: (1) the increasing uptake of
glucose by elevated expression of Glucose transporter-1 (GLUT1)
and Sodium Glucose Cotransporter-1 (SGLT1); (2) active ATP
generation reaction by up-regulation of phosphoglycerate kinase
(PGK) and pyruvate kinase (PK); (3) regeneration of NAD+ by
lactate dehydrogenase (LDH); and (4) out-transport and re-uptake
of lactate by monocarboxylate transporter (MCT), mainly MCT1
and MCT4 [5,6,7]. Most enzymes’ activities in the pathway are
controlled by two factors including c-myc and HIF-1a [8,9]. Many
reports have demonstrated an increased level of activities of the
glycolytic enzymes in various types of tumors and cancer cell lines
such as GLUT1, hexokinase, MCTs and HIF-1a [10]. In addition,
silencing of these over-expressed enzymes, such as pyruvate kinase
(PKM2), have been documented for inhibiting cancer cell
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proliferation effectively, inducing apoptosis and reversing multi-
drug resistance [11,12]. Therefore, developing novel glycolysis
inhibitors is an important direction in current cancer research.
Some glycolysis inhibitors such as 2-deoxy-glucose and 3-bromo-
pyruvate have already been approved for clinical trials [5].
In recent years, LDH-A is also emerging as a novel cancer
therapeutic target. Numerous studies have demonstrated the over-
expression of LDH-A in various types of cancer including renal,
breast, gastric and nasopharyngeal, etc [13,14,15]. Considering
the important role of LDH-A in maintaining NAD+ regeneration,
its inhibition might lead to energy production blockade in cancer
cells. Several studies have found that LDH-A suppression in
cancer cells result in the reactive oxygen species (ROS) burst,
mitochondrial pathway apoptosis and limited tumorigenic abilities
[15,16]. LDH-A is an effective target for cancer therapy because
its expression is largely confined to skeletal muscle. Moreover,
human subjects with LDH-A deficiency show no apparent diseases
except myoglobinuria under intense anaerobic exercise [17].
Therefore it is promising to develop novel LDH-A inhibitors. In
fact, gossypol, a polyphenolic compound initially applied as male
anti-fertility agent, has been demonstrated to possess the property
of anti-LDH-A activity since several years ago [18]. However, the
significant toxicities induced by gossypol (including cardiac
arrhythmias, renal failure, muscle weakness and even paralysis)
have stopped its further development in that direction. To identify
a natural lead compound with less toxicity therefore becomes a
focus in anti-LDH-A drug discovery.
Traditional Chinese Medicine (TCM) is particularly appreciat-
ed for cancer therapy in China. With the existence of between
250,000 to 300,000 plant species in the world, Chinese herbal
medicine provides a fast track and important source for drug
discovery and is becoming more and more acceptable around the
world [19]. In TCM system, Spatholobus suberectus Dunn. (SS) is the
representative herb which is believed to fight against cancer via
modulating tumor microenvironment, such as relieving blood
stasis, improving hypoxia and decreasing lactic acid accumulation,
etc. Clinical and laboratory trials also demonstrated that the herb
extracts could improve hematopoiesis and enhance immunity in
cancer patients after they complete chemotherapy or radiotherapy
[20,21]. Some studies also indicated that the herb extracts could
inhibit the proliferation of various cancer cell lines in vitro [22].
Chemical analysis found that SS contained flavonoids, phenolic
compounds, quinones, and saponins [23,24]. However, there still
lacks strong evidence at present to support the application of SS in
anti-cancer therapy. In addition, since there might exist hundreds
of phytochemicals in a single herb, it is difficult to determine the
actual bioactive anti-cancer compounds in SS. In recent years,
target-based strategy is becoming an important tool for designing
novel drugs or seeking bioactive lead compounds from natural
resources. Herein, we applied the bioactivity-guided fractionation
targeting on LDH-A to elucidate the active compounds in SS.
In the present study, we demonstrated the LDH-A inhibition
activities of SS on breast cancer by both in vitro and in vivo assays.
Meanwhile, epigallocatecin (EGC) was validated as the key
compound in SS accounting for the inhibited LDH-A activity by
bioactivity-guided fractionation based on LDH-A activity, LDH-A
expression and apoptosis. Mechanism studies revealed that
disassociation of Hsp90 from HIF-1a and subsequent accelerated
HIF-1a proteasome degradation might lead to the LDH-A
inhibition induced by epigallocatechin. Our study sheds novel
light on the medicinal application of SS and the potential
development of epigallocatechin as LDH-A inhibitors in breast
cancer treatment.
Materials and Methods
Cell culture
Human breast cancer cell line MCF-7 and MDA-MB-231 were
obtained from the American Type Culture Collection. The cells
were cultivated in medium (DMEM for MCF-7; L-15 for MDA-
MB-231) supplemented with 10% FBS and 1% penicillin and
streptomycin at 37uC in a humidified incubator with 5% CO2 or
without CO2.
Preparation of SS aqueous extracts
SS (bought from Guang Xi Province and identified by the
Institute of Botany, The Chinese Academy of Sciences) was cut
into small pieces and immersed in distilled water. The mixture was
treated by ultrasound for 1 hr followed by heating at 100uC for
30 mins twice. The supernatants were concentrated by rotary
evaporation and kept overnight at280uC. The frozen supernatant
was then placed in the freezing dryer for 48 h to get the raw
aqueous extract powder. The production ratio of SS was 10.2–
11.0%. HPLC analyses of different batches of SS aqueous extracts
were compared to guarantee repetitive production. The powder
was dissolved in phosphate buffer solution and passed through
0.45 mm filter for later use.
Flow cytometry analysis
For apoptosis assay, cells were seeded on 6 well plates at a
density of 56105/well. After drug treatment for 48 h, cells were
stained with Annexin V-Cy5 (Biovision, Mountain View, CA) for
15 mins at room temperature. The apoptotic index was deter-
mined by flow cytometry (BD Bioscience) with FlowJo software.
Mitochondrial membrane potential Dym was assessed with the
fluorescent probe JC-1 (Molecular probe, Eugene, OR). The
mitochondrial J-aggregated form, presenting as red fluorescence,
will be assessed by flow cytometry. For superoxide (O2
2) level
detection, probe hydroethidine (140 mg/mL, Polysciences, War-
rington, PA) was applied, which will be enzymatically dehydro-
genated to form ethidium after interacting with superoxide.
Cellular oxygen consumption
Breast cancer cells (56106) were re-suspended in 3 ml PBS
supplemented with 25 mM glucose, 1 mM pyruvate and 2% BSA.
Cellular respiration of normal and drug-treated cancer cells were
measured by a Clark oxygen electrode (YSI, Ohio, US), which was
placed in a sealed respiration chamber. All samples were assayed
in triplicate for 20 mins to generate an oxygen consumption curve.
LDH-A activity assay
Based on detection of absorption value of b-NADH at 340 nm,
in vitro LDH-A enzymatic system was established. In a 3 ml
reaction mix, the final concentrations were 100 mM sodium
phosphate, 0.12 mM b-NADH, 2.3 mM pyruvate, 0.033% (W/V)
bovine serum albumin and 20 mg of total protein extracts in
control or drug-treated cancer cells. The value of A340 nm was
continuously recorded for 5 mins at 37uC. The LDH-A activity
was calculated according to the formula: Units/mg= (DA340 nm/
min TEST - DA340 nm/min BLANK) * 3* df/6.22 * 0.1 * PC,
where 3 is the total volume of assay, df is the dilution factor, 6.22 is
the millimolar extinction coefficient of b-NADH at 340 nm, 0.1 is
the volume of added protein extracts and PC is the protein
concentration.
SS Inhibiting Breast Cancer via LDH-A
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Immunoblotting analysis
Western blotting analysis was performed as described previously
[15]. Quantified protein lysates (20 mg) were resolved in SDS-
PAGE gel and transferred onto PVDF membrane (Millipore,
Billerica, MA). The protein blot was then blocked in 5% BSA for
2 h, washed with TBS and then incubated overnight with primary
antibody at 4uC. After incubating with secondary antibody for 2 h
at room temperature, Immunoreactions were visualized with ECL
advance (GE Healthcare) reagents and quantified by Quantity
One software.
PCR analysis
Total RNA in control or drug treated cancer cells were
extracted using TRIzol reagent (Invitrogen) and reverse transcrip-
tion were carried out using first strand CDNA synthesis kit
(Fermentas) according to the manufacturer’s instruction. For RT-
PCR analysis, Gotaq green master mix (Promega) was used to
amplify the interesting genes. The primers for LDH-A and b-actin
were designed as follows: LDH-A, forward primer: 59-
GGACTTGGCAGATGAACTTG-39, reverse primer: 59-TCA-
GAG AGACACCAGCAACA-39; b-actin forward primer: 59-
CTGGGACGACATGG AGAAAA-39, reverse primer: 59-AAG-
GAAGGCTGGAAGAGTGC-39. Real-time PCR analysis was
performed using a SYBR Green kit (Fermentas) on Roche
lightcycler 480 detector. The primers for HIF-1a and b-actin
were designed as follows: HIF-1a, forward primer: 59-
TTTTTCAAGCA GTAGGAATTGGA-39, reverse primer: 59-
GTGATGTAGTAGCTGCATGATCG-39; b-actin forward
primer: 59-CCAACCGCGAGAAGATGA-39, reverse primer:
59-CCAGAGGCGTACAGGG ATAG-39. Ct value was mea-
sured during the exponential amplification phase. The relative
expression level (defined as fold change) of target gene was given
by 22DDCt and normalized to the fold.
Bioactivity-guided fractionation and identification of
bioactive anti-cancer compounds in SS
Crude aqueous extracts of SS were firstly subjected to different
polar solvents to yield petroleum ether partitioned extract (PE),
ethyl acetate partitioned extract (EtOAc), n-butanol partitioned
extract (BuOH) and water residues (RE). Each fraction was
vacuum dried and set as the same concentration (50 mg/ml) in
phosphate buffer solution for later screening by Annexin V-Cy5
staining, LDH-A activity and LDH-A expression as described
previously. EtOAc fraction was further separated by marcoporous
resin column and chromatographied into 12 sub-fractions. The
eluted solution was set as H2O, 20%ETOH, 40%ETOH,
60%ETOH, 80%ETOH and 95% ETOH. HPLC analysis of
each sub-fraction was conducted as described previously. After
second-round screening, the peaks in the candidate sub-fractions
were collected by preparative HPLC column (Kromasil C18
Media, 10 nm, 5 mm, 20.0*250 mm). Through further HPLC
analysis, the peaks with high purity were subjected to identification
by ESI-MS (Thermo LCQ DECA XP) and NMR (BRUKER
AVANCEIII 400 MHz).
Immunoprecipitation assay
For immunoprecipitation assay, Immunoprecipitation kit-Dy-
nabeads Protein G (Invitrogen) was applied. Control or drug
treated cancer cells were lysed in RIPA buffer. Followed by
centrifugation, the supernatants were collected and incubated with
protein G dynabeads, which was binding to antibody (Hsp90) in
advance. After incubating at room temperature for 2 h, the
Dynabeads-Ab-Ag complex were washed three times with
provided washing buffer and denaturized for following immuo-
blotting experiments.
Establishment of LDH-A overexpression cells
The full-length cDNA of LDH-A were amplified and subcloned
into the pcDNA3.1 (+) vector (invitrogen) using the EcoRI and
XhoI restric enzyme sites. The primers for LDH-A were designed
as follows: upstream: 59-ATATGAATTCA TGGCAACTC-
TAAAGG-39, downstream: 59-GCGGCCTCGAGT-
TAAAATTGC AGCTCCT-39. After PCR and DNA sequencing
validation, the positive plasmids were co-transfected into breast
cancer cells using Turbofectin8.0 and empty vector was used as a
control. After 48 h of co-incubation, transfected cells were selected
in primary cell cultivated medium containing 400 mg/ml genet-
icin. After 2 to 3 weeks, single independent clones were randomly
isolated, and each individual clone was plated separately. After
clonal expansion, cells from each independent clone were tested
for LDH-A expression by Western blotting.
Breast cancer xenografts
All animal studies involving animal experiments were reviewed
and approved by the University of Hong Kong’s Committee for
Ethical Review of Research. Both MCF-7 and MDA-MB-231 cells
were re-suspended at 56106 cells/100 ml in PBS and injected into
the fourth mammary gland fat pad of 4–5 week-old female nude
mice. In the MCF-7 xenograft, 17b-estrogen (Sigma, St. Louis,
MO) was given subcutaneously at a dose of 1.5 mg per animal at
three-day intervals. After the tumors reached approximately
1 cm3, they were cut into 5 mm3 pieces and then transplanted
to mammary glands respectively. Mice were divided into control
and drug-treated groups (6 mice per group). SS was given by oral
intake at a dose of 1 g/kg/d. The identified bioactive compounds
will be given by intraperitoneal injection at low and high dose per
day. Tumors were measured at three-day intervals with a caliper,
and tumor volume was calculated using the following formula:
volume (mm3) =width26length/2. Body weight was also moni-
tored every three days as an indicator of the overall health of the
animals. Blood from mice in SS experiment was collected in
sodium heparin coated tubes for blood toxicity assay using
hemocytometer (XS-800i, Sysmex, Japan). Tumor tissues were
removed at the end of the experiment and subjected to
immunohistochemistry study, histological analysis and western
blotting analysis.
Immunohistochemistry and TUNEL analysis
Tumor samples obtained from in vivo studies were rinsed in PBS
and fixed in 4% paraformaldehyde/PBS. Samples were dehydrat-
ed in gradient ethanol, paraffin embedded, and sectioned (4 um).
Deparaffinized sections were stained for primary antibodies. The
samples were incubated overnight with biotinylated secondary
antibodies. Detection was done with avidin-biotin-HRP complex
(Thermo scientific, Fremont, CA) and di-aminobenzidine as
chromogen. Nuclei were counterstained with hematoxylin. Anti-
gen-positive cells were counted in six fields per tumor sample.
Results are expressed as the average 6 SD of tumors per group.
For TUNEL analysis, sections were permeabilized with 0.1%
Trition X-100 plus 0.1% sodium citrate and then incubated with
50 ml TUNEL reaction mixture (Roche) at 37uC for 60 minutes.
After rinsing with PBS three times, 50 ml Converter-POD was
added and the tissue cells were incubated in a humidified chamber
for 30 minutes at 37uC. DAB substrate was then added, followed
by counterstaining with hematoxylin. The assay included negative
controls (without terminal transferase). Apoptosis was quantified
SS Inhibiting Breast Cancer via LDH-A
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by counting the number of TUNEL-positive cells in at least six
non-overlapping high-power fields on each section and evaluated.
Statistic analysis
The data were expressed as Mean6SD. A two-tailed Student’s
t-test was used to examine the significance of the data between
groups. Statistical significance was considered when the P
value,0.05.
Results
SS induces breast cancer cell apoptosis, G2/M checkpoint
arrest, ROS accumulation and LDH-A inhibition
Apoptosis-induction effect is an important parameter for
discovery of anti-cancer agents. In our study, as shown in
Figure 1A, SS could dose-dependently induce apoptosis in both
MCF-7 and MDA-MB-231 cells after 48 h administration.
Meanwhile, JC-1 staining also showed that the mitochondrial
membrane potential Dym was lowered after SS administration,
indicating that the mitochondrial pathway apoptosis was activated
(Figure 1B). Cell cycle analysis showed that in SS treated breast
cancer cells, there has a significant increase in G2/M subpopu-
lation, implying that the G2/M checkpoint was arrested by SS
(Figure 1C).
As ROS has been reported as an important inductor of
apoptosis and DNA damage, and O2
2 accumulation was observed
as an important subsequent event following LDH-A inhibition,
hydroethidine was applied to detect the change of intracellular
O2
2 level after SS administration. As shown in Figure 1D, the
fluorescence intensity of O2
2 was highly elevated by SS in both
breast cancer cells. In addition, oxygen consumption assay also
revealed that the oxygen consumption speed was significantly sped
up in SS treated cancer cells, indicating that the intracellular
LDH-A activity might be suppressed by SS and the mitochondrial
metabolism might be activated (Figure 1D, lower panel).
In order to see whether SS has inhibition effects on LDH-A in
cancer cells, the LDH-A activity of both breast cancer cells was
examined after SS administration. The results showed that SS
could suppress LDH-A activity in both cancer cells in a dose- and
time-dependent manner (Figure 1E). In addition, western blotting
results showed that LDH-A expression was gradually inhibited
with the increasing dose of SS. In order to see whether SS still
possesses LDH-A inhibition effects under a hypoxic environment,
a 0.5% O2 environment was created by importing nitrogen and
5% carbon dioxide into a sealed oxygen chamber. The LDH-A
expression in both breast cancer cell was detected following SS
administration for 6 h under hypoxia. The results showed that
although LDH-A expression was up-regulated due to hypoxia
stimulation, SS could also inhibit LDH-A expression in a dose-
dependent manner (Figure 1F).
SS inhibits breast cancer growth and LDH-A expression in
vivo
To determine whether SS could inhibit cancer growth in vivo,
human breast cancer orthotopic xenografts were built in nude
mice. As shown in Figure 2A, SS significantly inhibited both
cancer growth with 64.60% and 51.94% inhibition ratio on MDA-
MB-231 and MCF-7 breast cancer xenografts respectively.
Meanwhile, the tumor weight in SS containing group was
significantly reduced in comparison with the control group
(Figure 2B). In both cancer xenografts, significant body weight
loss and blood toxicity did not appear in SS containing groups
(Figure 2C & D). Immunohistochemistry assay showed that the
LDH-A expression was suppressed in SS-treated tumor samples,
while apoptosis ratio was greatly elevated (Figure 2E). All these
results indicated that SS could inhibit cancer growth and LDH-A
expression in vivo.
Bioactivity-guided fractionation of SS
In order to determine the bioactive compounds in SS,
molecular-targeted screening based on LDH-A activity, LDH-A
expression and apoptosis were carried out. The bioactivity-guided
process was summarized in Figure 3A. Crude 60% ethanol
extracts of SS were firstly subjected to different polar solvents to
yield PE, EtOAc, BuOH and RE fractions. The first round
screening identified EtOAc fraction as the subset with the strongest
LDH-A inhibition effects. EtOAc fraction was further separated
by Octadecylsilyl (ODS) column and chromatographied into 12
sub-fractions. After the second round screening, the sub-fraction 4
was finally identified as the best subset (Supplementary Figure S1).
Preparative HPLC column was applied to purify bioactive
compounds in sub-fraction 4. Finally a total of 7 peaks were
collected. Through HPLC analysis, the peaks including 1, 3, 5 and
6 showed high purity, therefore we conducted chemical identifi-
cation on them by mass and NMR. The four compounds were
validated as gallocatechin (GC), epigallocatechin (EGC), catechin
(C) and epicatechin (GC) (Figure 3B). Detailed structure informa-
tion were listed as followings: Peak 1 (gallocatechin, GC): UV
lmax: 215, 270 nm, MS: m/z 305 [M-H]-; 1H NMR (400 MHz,
DMSO): d 9.14 (s, 1H, -OH), 8.91 (s, 1H, -OH), 8.75 (s, 2H, -
OH), 7.99 (s, 1H, -OH), 6.24 (s, 2H, H-29, H-69), 5.88 (br s, 1H,
H-6), 5.69 (br s, 1H, H-8), 4.83 (d, J = 4.9 Hz, 1H, 3-OH), 4.42 (d,
J = 6.9 Hz, 1H, H-2), 3.80–3.74 (m, 1H, H-3), 2.61 (dd, J = 16.0,
5.0 Hz, 1H, H-4), 2.34 (dd, J = 15.9, 7.4 Hz, 1H, H-4).13C NMR
(100 MHz, DMSO) d 156.4, 156.1, 155.2 (C-5, C-7, C-8a), 145.6
(C-39, C-59), 132.4 (C-49), 129.8 (C-19), 105.9 (C-29, C-69), 98.9
(C-4a), 95.0 (C-6), 93.8 (C-8), 81.0 (C-2), 66.3 (C-3), 27.4 (C-4);
Peak 3 (epigallocatechin, EGC):UV lmax: 215, 271 nm, MS: m/z
305 [M-H]-, 1H-NMR (400 MHz, DMSO): d 9.09 (s, 1H, 5-OH),
8.89 (s, 1H, 7-OH), 8.69 (s, 2H, 39-OH, 49-OH), 7.93 (s, 1H, 59-
OH), 6.37 (s, 2H, 29,69-H), 5.88 (d, J = 2.2 Hz, 1H, 6-H), 5.71 (d,
J = 2.2 Hz, 1H, 8-H), 4.65 (s, 1H, 2-H), 4.60 (d, J = 4.6 Hz, 1H, 3-
OH), 3.98 (m, 1H, 3-H), 2.66 (dd, J = 16.3, 4.4 Hz, 1H, 4-H), 2.45
(d, J = 3.3 Hz, 1H, 4-H). 13C NMR (100 MHz, DMSO) d 156.5,
156.2, 155.7 (C-5, C-7, C-8a), 145.3 (C-39, C-59), 132.1 (C-49),
129.7 (C-19), 106.0 (C-29, C-69), 98.5 (C-4a), 95.0 (C-6), 94.1 (C-8),
78.1 (C-2), 65.0 (C-3), 28.1 (C-4). Peak 5 (catechin, C): UV lmax:
215, 276 nm, MS: m/z 289 [M-H]-, 1H-NMR (400 MHz,
DMSO): d 9.17 (s, 1H, 5-OH), 8.93 (s, 1H, 7-OH), 8.85 (s, 1H,
39-OH), 8.81(s, 1H, 49-OH), 6.70(m, 1H, 29-H), 6.60 (d,
J = 1.9 Hz, 1H, 59-H), 6.58(d, J = 1.9 Hz, 1H, 69-H),5.88 (d,
J = 2.3 Hz, 1H, 6-H), 5.68 (d, J = 2.2 Hz, 1H, 8-H), 4.86 (d,
J = 5.1 Hz, 1H, 3-OH), 4.47 (d, J = 7.5 Hz, 1H, 2-H), 3.82 (m, 1H,
3-H), 2.65 (dd, J = 16.1, 5.3 Hz, 1H, 4-H), 2.34 (dd, J = 16.0,
8.0 Hz, 1H, 4-H); 13C-NMR (400 MHz, DMSO): d 156.88 (C-7),
156.59 (C-5), 155.78 (C-8a), 145.85 (C-39, 49), 131.01 (C-19),
118.85 (C-69), 115.49 (C-29), 114.95 (C-59), 99.47 (C-4a), 95.52 (C-
6), 94.25 (C-8), 81.43 (C-2), 66.74 (C-3), 28.31 (C-4). Peak 6
(epicatechin, EC): UV lmax: 203, 278 nm MS: m/z 289 [M-H]-,
1H-NMR (400 MHz, DMSO): d 9.13 (s, 1H, 5-OH), 8.93 (s, 1H,
7-OH)), 8.80 (s, 1H, 39-OH), 8.72 (s, 1H, 49-OH), 6.88 (s, 1H, 29-
H), 6.65 (m, 2H, 59, 69-H), 5.89 (d, J = 2.1 Hz, 1H, 6-H), 5.71 (d,
J = 2.1 Hz, 1H, 8-H), 4.73 (s, 1H, 2-H), 4.68 (d, J = 2.7 Hz, 1H, 3-
OH), 3.98 (m, 1H, 3-H), 2.67 (dd, J = 16.2, 3.8 Hz, 1H, 4-H),
2.45(dd, J = 16.0, 2.2 Hz, 1H, 4-H). 13C-NMR (400 MHz,
DMSO): d 156.96 (C-7), 156.66 (C-5), 156.21 (C-8a), 144.90 (C-
39, 49), 131.04 (C-19), 118.37 (C-69), 118.37(C-29), 115.32(C-59),
98.91 (C-4a), 95.48 (C-6), 94.50 (C-8), 78.49 (C-2), 65.34 (C-3),
SS Inhibiting Breast Cancer via LDH-A
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28.66 (C-4).The concentrations of the four compounds in the sub-
fraction 4 were determined as 0.59% (GC), 1.46% (EGC), 12.36%
(C) and 12.04% (EC), respectively.
Among the four compounds, EGC showed the highest LDH-A
inhibition effects, while the other three did not (Figure 3C). In
order to see whether EGC has synergistic effects with GC, C and
EC, the four compounds were put together according to their
concentration ratio in the mixture (EGC: GC: EC:
C=25 mM:10 mM:200 mM:200 mM). As shown in Figure 3D,
EGC showed significant synergistic effects with the other three
catechins. However, when EGC was withdrawn, the inhibition
effects disappear, indicating that EGC might be the key compound
in SS accounting for the LDH-A inhibition effect.
EGC induces breast cancer cells apoptosis via LDH-A
To validate the effects of EGC on LDH-A activity and
expression, in vitro enzymatic activity assay and western blotting
were applied together to detect the EGC effects on LDH-A. The
results showed that the LDH-A activity and expression in both
breast cancer cells were down-regulated in a dose-dependent
Figure 1. SS induces breast cancer cell apoptosis, G2/M checkpoint arrest, ROS accumulation and LDH-A inhibition. (A) Annexin-Cy5
staining results showed that SS induced both breast cancer cells apoptosis in a dose-dependent manner; (B) JC-1 staining assay indicated that
mitochondrial membrane potential was decreased after SS treatment, indicating that the mitochondrial pathway apoptosis was triggered by SS; (C)
Cell cycle analysis showed that after SS treatment, the G2/M checkpoint was arrested in both breast cancer cell lines, presenting as a significant
increase in G2/M subpopulations; (D) Hydroethidine was applied to detect the intracellular O2
2 level after SS administration by flow cytometry. The
results showed that the intracellular O2
2 level was increased after SS treatment for 24 h (upper panel). Clark oxygen electrode was applied to detect
the oxygen consumption speed of breast cancer cells after SS treatment. The results showed that the oxygen consumption speed of both breast
cancer cells was rapidly enhanced after SS administration (lower panel); (E) LDH-A activity assay showed that SS were dose- and time- dependent
when suppressing the LDH-A activity; (F) Western blotting results indicated that after SS administration, the expression of LDH-A in both breast
cancer cells under both normoxia and hypoxia condition were down-regulated.
doi:10.1371/journal.pone.0056631.g001
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manner after EGC treatment under both normoxic and hypoxic
condition (Figure 4A & B). RT-PCR results revealed that EGC
also inhibited LDH-A mRNA levels, indicating that the decreased
LDH-A activity might happen at the transcriptional level
(Figure 4C).
In order to validate the critical role of LDH-A in EGC-induced
apoptosis, we compared the apoptotic events in parental and
LDH-A over-expression cancer cells. The results showed that
LDH-A over-expression reduced apoptosis induced by EGC
detecting by Annexin V-Cy5 staining (Figure 4 D). Meanwhile,
the high-elevated O2
2 level induced by EGC was also down-
regualted in LDH-A over-expression cancer cells, implying that
LDH-A might be a key molecular target in the EGC-induced
apoptosis (Figure 4E).
EGC promotes HIF-1a proteasome degradation via
HSP90
HIF-1a is reported as an important regulator of LDH-A. Since
HIF-1a has the strongest expression at the 6th hour under hypoxia,
we selected the 6th hour for HIF-1a—EGC interaction study
(Figure 5A). The results showed that EGC inhibited HIF-1a
expression under both hypoxic and hypoxic mimic microenviron-
ment created by CoCl2 (Figure 5 B). In order to validate whether
EGC had influences on HIF-1a mRNA expression, Q-PCR
analysis was carried out. The results showed that there was little
expression changes on HIF-1a mRNA levels after 50 mM EGC
treatment (Figure 5C).
Besides transcription regulation, HIF-1a protein level was also
influenced by post-translational processes. PI3K/Akt/mTOR and
proteasome degradation pathway were reported as the most
important regulators. Since previous study demonstrated that
there was little expression of phosphor-Akt in breast cancer cell
lines MCF-7 and MDA-MB-231 [25], we therefore focused on the
HIF-1a proteaosme degradation pathway. Cycloheximide, a
protein synthesis inhibitor, was firstly added with or without
EGC to treat breast cancer cells. The results showed that in both
breast cancer cells, the HIF-1a degradation speed was much faster
in the EGC treated group than that in the control groups,
indicating that the proteasome degradation pathway might be
activated (Figure 5D). In order to validate the role of proteasome
degradation in HIF-1a down-regulation caused by EGC, the
proteasome inhibitor MG132 was then administrated to breast
cancer cells. The results showed that the HIF-1a accumulation
level was similar in EGC treated or untreated groups, indicating
that the accelerated proteasome degradation pathway was mainly
accouting for HIF-1a down-regulation induced by EGC
(Figure 5E). Meanwhile, the increased ubiquinated- HIF-1a in
EGC treated samples also supported that EGC promoted the HIF-
1a proteasome degradation (Figure 5F).
HIF-1a belongs to the Per-ARNT-Sim basic helix-loop-helix
family and interacts with Hsp90. It is well demonstrated that
Figure 2. SS inhibits breast cancer growth in vivo. (A) Tumor growth curve of both cancer xenografts during therapy period. The results
indicated that SS (1 g/kg/d, oral intake) could significantly inhibit tumor growth in both ER negative and positive breast cancers; (B) Representative
tumor pictures in control and SS treated groups. The average of tumor weight in SS treated group was significantly decreased in comparison to that
in the control group; (C) Body weight fluctuation influenced by SS. SS-treated group had little influences on body weight compared to the control
groups; (D) Blood routine quantity assay revealed that SS has little blood toxicity effects on mice; (E) Immunohisotchemistry method was applied to
detect the LDH-A expression in both control and SS treated groups. The results indicated that LDH-A expression in both SS-treated breast cancer
xenografts were significantly reduced, while TUNEL analysis indicated that the apoptosis ratio in SS –treated tumor samples was significantly
increased. (6100, scale bar = 50 um; All values represents as Mean6SD, n = 6, *P,0.05 vs. control).
doi:10.1371/journal.pone.0056631.g002
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binding with Hsp90 can enhance HIF-1a stability and prevent it
from degradation [26,27]. The results from immunoblotting assays
firstly demonstrated that EGC brought little influences on Hsp90
expression in both breast cancer cells. Further immunoprecipita-
tion assay showed that EGC inhibited binding of HIF-1a to
Hsp90. Meanwhile, the disassociation of HIF-1a from Hsp90 was
demonstrated as an early event happened as early as 30 mins after
EGC administration. However, the downregualtion of total HIF-
1a was shown to happen at 2 h after EGC treatment, suggesting
that EGC promotes HIF-1a degradation via interfering with the
interaction between Hsp90 and HIF-1a (Figure 5F).
EGC inhibits breast cancer growth and LDH-A expression
in vivo
To determine whether or not EGC could inhibit HIF-1a/LDH-
A expression in vivo, human breast cancer xenografts were built. As
shown in Figure 6 A, EGC administration significantly limited
cancer growth in a dose-dependent manner. Immunohistochem-
istry assay showed that the LDH-A, HIF-1a and Ki67 expression
were all inhibited in EGC-treated tumor samples, while the
apoptosis ratio was significantly elevated (Figure 6 B). Western
blotting assay further demonstrated that both LDH-A and HIF-1a
expression were down-regulated in EGC-treated tumor samples,
which is consistent with immunohistochemistry results (Figure 6C,
left panel). In addition, LDH-A enzymatic assay also revealed that
the LDH-A activity of EGC-treated tumor samples was signifi-
cantly decreased in comparison to that of the control group
(Figure 6C, right panel). In order to see whether EGC had
inhibition effects on LDH expression in other tissues and organs,
we selected skeletal muscle and heart tissues, the two typical LDH
expression places, to detect the influences. The results showed that
EGC brought little influences on LDH expression and morphol-
ogy of these tissues, indicating that EGC had little toxic effects
(Figure 6D).
Discussion
Targeting on hypoxia and glycolytic related genes has become
an important strategy for cancer therapy and drug development.
Figure 3. Bioactivity-guided fractionation of SS targeting on LDH-A. (A) Isolation scheme of SS. Three parameters including LDH-A activity,
LDH-A expression and apoptosis were selected for bioactive compounds screening; Crude 60% ethanol extracts of SS were firstly subjected to
different polar solvents to yield PE, EtOAc, BuOH and RE fractions. After the first round screening, the EtOAc fraction was further separated with
macroporous resin to yield 12 subfractions. Following the second round screening, subfraction 4 was then subjected to preparative HPLC and four
compounds were finally purified. (B) Preparative HPLC chromatography of subfraction 4. A total of 7 single peaks were identified and the peaks 1, 3, 5
and 6 were finally purified through preparative HPLC. After Mass and NMR identification, the four compounds were identified as gallocatechin,
epigallocatechin, catechin and epicatechin; (C) Among the four compounds, EGC exhibited the highest activity in inhibiting LDH-A expression; (D)
EGC played synergistic role with the other three compounds in inhibiting LDH-A expression. The four compounds were added sequentially according
to their relative concentrations in SS (10 mM : 25 mM : 200 mM : 200 mM). When the four compounds were put together, they showed the highest
inhibition effects on LDH-A expression. However, when EGC was withdrawn, the inhibition effects significantly weakened, indicating that EGC might
play a key role in inhibiting LDH-A activity.
doi:10.1371/journal.pone.0056631.g003
SS Inhibiting Breast Cancer via LDH-A
PLOS ONE | www.plosone.org 7 February 2013 | Volume 8 | Issue 2 | e56631
LDH-A is a hypoxia response gene and its over-expression has
been demonstrated in numerous types of cancer. LDH-A silencing
was reported to induce cancer cells death by recent studies. Given
that LDH-A inhibition has little toxic effects on normal human
tissues, it might be an ideal therapeutic target for cancer treatment
and it is of great interest to develop its natural inhibitors from
plants. Through long-history clinical application, TCM has well
been accepted by pharmacologists and oncologists as a valuable
database to screen bioactive compounds for novel drug discovery.
In TCM system, SS is believed to modulate tumor hypoxia
microenvironment and has long been recommended for cancer
therapy. However, the anti-cancer mechanisms of SS and its
bioactive compounds still remain unclear.
In our present study, we firstly demonstrated the inhibition
effects of SS on LDH-A activity using in vitro and in vivo models.
Previous study has demonstrated that in LDH-A knockdown
breast cancer cells, the oxygen consumption was demonstrated
greatly speeded up [15]. As the OXPHOS chains in the
mitochondrion of cancer cells are mutated in comparison with
those of normal cells, the OXPHOS chain activation will make
more electrons leak and form reactive oxygen species after
combining with oxygen, which finally destroy the mitochodnrial
membrane and induce mitochondrial pathway apoptosis. LDH-A
was therefore considered as an upsteam factor accounting for
ROS burst and mitochondrial pathway apoptosis [16]. We firstly
detected the apoptosis and intracellular ROS level following SS
treatment. The results showed that the mitochondrial pathway
apoptosis was triggered after SS administration for 48 h,
accompanying with elevated ROS level and accelerated oxygen
consumption. All these results indicated that the LDH-A activity
might be inhibited by SS. The results from enzymatic reaction
system and Western blotting revealed that SS could inhibit both
LDH-A activity and expression in a time- and dose- dependent
manner. Interestingly, SS interestingly exhibited stronger inhibi-
tory effects on the activity and expression of LDH-A in MDA-MB-
231 cells than it did in MCF-7 cells, implying that ER negative
cells might be more sensitive to SS than ER positive ones.
Actually, the relation between LDH and ER has been studied
previously by other scientists, they found that the mean value of
LDH in ER+PR+ tumors was lower than in the ER-PR- subset
regardless of menopausal status [28]. In our study, we also found
that the LDH-A activity in MDA-MB-231 cells was greatly higher
than that of MCF-7. However, it can not say that ER could
negatively regulate LDH-A expression. Some studies also found
Figure 4. EGC inhibits breast cancer LDH-A activity and expression. (A) LDH-A activity assay was applied to detect the effects of EGC on
LDH-A activity in both breast cancer cell lines. The results indicated that EGC could dose- and time-dependently suppressed the LDH-A activity (All
values represents as Mean6 SD, n = 3, *P,0.05 vs. control); (B) The expression of LDH-A was also validated by Western blotting after EGC
administration. The results showed that SS could inhibit LDH-A expression under both normoxia and hypoxia condition; (C) RT-PCR method was
utilized to detect the level changes of LDH-A mRNA after EGC treatment. The results revealed that LDH-A mRNA levels were also down-regulated with
increasing dose of EGC under both normoxia and hypoxia conditions; (D) The full length cDNA of LDH-A were amplified and subcloned into the
pcDNA 3.1(+) vector. The over-expression of LDH-A was validated by Western blotting (upper panel). Annexin V-Cy5 staining analysis demonstrated
that the EGC- induced apoptosis was reduced in LDH-A over-expression breast cancer cells; (E) Hydroethidine staining assay also revealed that in
LDH-A over-expression breast cancer cells, the EGC-induced ROS elevation was also significantly eliminated.
doi:10.1371/journal.pone.0056631.g004
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that estrogen could positively control LDH expression in ER-
positive cells [29]. Therefore the regulatory network between ER
and LDH seems to be complicated, which might be controlled by
multiple factors. Whether ER will affect the activity of SS on
LDH-A might need further investigation. Given the hypoxic
microenvironment of cancer in vivo, we placed cancer cells in a
hypoxic chamber to validate whether SS could also result in a
similar LDH-A suppression or not. The results showed that a
similar LDH-A inhibition effect was observed. These results
indicated that SS might reach a similar anti-LDH-A effect in vivo.
In vivo study showed that SS could significantly inhibit breast
cancer growth. Immunohistochemistry results further showed that
the expression of LDH-A was significantly suppressed in groups
treated tumor samples, while the apoptosis ratio was elevated,
implying that SS could also inhibit cancer cell proliferation, LDH-
Figure 5. EGC promotes HIF-1a proteasome pathway degradation. (A) Expression curve of HIF-1a under hypoxia. The results showed that
the expression level of HIF-1a reached the peak at the 6th hour, but had a slight decrease after 10 hours; (B) EGC inhibited HIF-1a expression in a
dose-dependent manner in both breast cancer cells under both hypoxia condition and hypoxia mimic created by cobalt chloride; (C) Real-time PCR
analysis was applied to detect the influences of EGC on HIF-1a mRNA levels. The results showed that there were little changes on HIF-1a mRNA level
after EGC administration; (D) Cychloheximide (CHX) was administrated on breast cancer cells to inhibit protein synthesis. The expression of HIF-1a in
both control and EGC treated cancer cells were validated by western blotting. The results showed that the HIF-1a degradation speed was much faster
in EGC treated groups than in control groups, indicating that EGC might promote HIF-1a degradation; (E) MG132 was administrated on breast cancer
cells to block the proteasome activity. The levels of HIF-1a were determined after MG132 treatment in both control and EGC treated groups. The
results indicated that the accumulation quantities of HIF-1a were similar in both control and EGC treated groups, indicating that proteasome
degradation was the main pathway accounting for decreased HIF-1a expression; (F) The ubiquinated HIF-1a level in both control and EGC treated
group were detected by Western blotting. The results showed that EGC increased the expression level of ubiquinated HIF-1a in both cancer cells,
indicating that EGC promoted the HIF-1a proteasome degradation pathway; Meanwhile, the interaction between HIF-1a and Hsp90 were validated
by immunoblotting and immunoprecipitation assay. The results indicated that EGC brought little influences on Hsp90 expression. In EGC treated cell
samples, the levels of HIF-1a binding to Hsp90 were decreased in comparison to control groups. Meanwhile, the dissociation of HIF-1a from Hsp90
was demonstrated to be an early event happed before downrgulation of HIF-1a induced by EGC, implying that EGC promotes HIF-1a degradation via
interfering with the interaction between Hsp90 and HIF-1a. (All values represented as Mean6 SD, n = 3, *P,0.05 vs. control).
doi:10.1371/journal.pone.0056631.g005
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A expression and trigger apoptosis in vivo. It is of great interest to
seek the bioactive compounds in SS targeting on LDH-A.
Bioactivity-guided fractionation has been considered as a novel
strategy leading to drug discovery in recent years [30]. LDH-A
activity and expression were both suppressed by SS while LDH-A
expression was closely correlated to apoptosis. These three
parameters including LDH-A activity, LDH-A expression and
apoptosis were selected for bioactivity screening. Finally a sub-
fraction enriched in catechins was validated with the strongest
LDH-A inhibition and apoptosis induction effect. We further
isolated four compounds in the sub-fraction identified as GC,
EGC, C and EC. Among them, EGC exhibited the highest LDH-
A inhibition effect and GC, C, EC showed synergistic LDH-A
suppression effects with EGC. For the synergistic effect, since
catechins are considered as basic units of procyanidins, which are
oligomeric compounds formed by carbon-carbon bond interac-
tions between C, EC, EGC or other their derivatives. Therefore
we applied vanillin/H2SO4 assay to detect the procyanidins
concentrations in SS. The results showed that procyanidins
concentrations in ethanol extracts of SS is 51.0960.37%,
indicating that the catechins could form procyanidins in SS,
therefore exhibiting a synergistic effects when played together.
Catechins are defined as flavonoids compounds, and widely
distributed in various plants and fruits, such as green tea, grape
seeds, strawberries, etc [31,32]. Numerous epidemiological and
laboratory studies have indicated that catechins intake is beneficial
for cancer prevention, delaying cancer onset and eliminating
carcinogens [33,34]. The anti-cancer molecular mechanisms of
catechins are validated to occur in multiple pathways including
both direct and indirect interaction such as apoptosis triggering,
cell cycle arrest, angiogenesis inhibition, ROS induction, tyrosine
kinases inhibition and interruption of survival signaling pathways,
etc. Our study for the first time revealed that catechins could also
inhibit LDH-A activity in cancer cells.
In comparison to EGCG, little attention has been paid to the
anti-cancer effects and mechanisms of EGC, a more popular
poylphenolic compound in natural plants. Actually some studies
demonstrated that EGC has similar anti-cancer effects in
comparison with EGCG [35,36]. In the present study, we have
shown that EGC inhibited LDH-A expression and activity under
both normoxia and hypoxia conditions. The administration
concentration of EGC is equivalent to the reported EGCG
effective dose. Meanwhile, LDH-A over-expression significantly
reduced EGC-induced apoptosis, indicating that LDH-A might be
a critical molecule in mediating anti-cancer effects of EGC. HIF-
1a is the most important transcriptional regulator of LDH-A. HIF-
Figure 6. EGC inhibits breast cancer growth and LDH-A expression in vivo. (A) In MDA-MB-231 and MCF-7 breast cancer xenografts, EGC
(20 mg/kg/d and 40 mg/kg/d) dose-dependently inhibited breast cancer growth, but had little influences on mice body weight; (B) The expression of
LDH-A, Ki67 and HIF-1a in both control and EGC treated tumor samples were detected by immunohistochemistry. The results showed that in both
breast cancer xenografts, the expression levels of LDH-A, Ki67 and HIF-1a were decreased in comparison to that in control groups, while apoptosis
ratio was elevated in EGC-treated tumor samples detected by TUNEL method; (C) Western blotting analysis showed that the expression of HIF-1a and
LDH-A in EGC-treated tumor samples were significantly decreased in comparison with control groups (left panel). The LDH-A activity in control and
EGC-treated tumor samples were determined. The results showed that there was a significant reduction in LDH-A activity in EGC-treated tumor
samples (right panel); (D) HE staining and immunohistochemistry assay indicated that EGC had little influences on the morphology and LDH
expression in muscle and heart (6100, scale bar = 50 um; All values represents as Mean6 SD, n = 6, *P,0.05 vs. control).
doi:10.1371/journal.pone.0056631.g006
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1a activates LDH-A expression by binding to the hypoxia
response element in the LDH-A promoter region. Herein, we
firstly found that EGC could inhibit HIF-1a expression under both
hypoxia and hypoxia mimic conditions, while there are little
changes on its mRNA expression level, indicating that protein
degradation might be a main mechanism accounting for HIF-1a
down-regulation. The following experiments revealed that EGC
sped up HIF-1a proteasome degradation. Hsp90, a chaperone
protein, has been shown to stabilize HIF-1a [37,38]. EGC was
found to inhibit the binding of HIF-1a to Hsp90. Meanwhile, the
disassociation of HIF-1a from HSP90 was demonstrated to be an
early event before HIF-1a degradation induced by EGC,
suggesting that EGC promotes HIF-1a degradation by interfering
with the interaction between HIF-1a and Hsp90. Besides protein
degradation, multiple cellular signaling pathways were also
involved in the regulation of HIF-1a stabilization and transactiva-
tion, such as PI3K/Akt pathways [39]. However, there is little
phosphor-Akt expression in both breast cancer cells demonstrated
by previous studies [25]. Therefore, whether or not EGC can
interrupt the PI3K/Akt signaling pathway might need further
study on other cancer models.
In consistent with in vitro findings, in vivo study also revealed that
EGC could dose-dependently inhibit tumor growth on both
cancer xenografts without bringing significant toxic effects such as
body weight loss. The expression of HIF-1a, LDH-A and Ki67
were all down-regulated, while apoptosis ratio was elevated in
EGC-treated tumor samples, implying that EGC also interrupted
the HIF-1a/LDH-A pathway in vivo.
Tumor energy supply is critical for maintaining its proliferation,
angiogenesis and metastasis. Glycolysis inhibition has been
considered as an important strategy for cancer therapy. In this
study, we have shown that SS possessed significant anti-cancer
effects via LDH-A inhibition both in vitro and in vivo. EGC was
validated as the key compound in SS by targeting on LDH-A, the
mechanism of which is closely correlated to accelerated HIF-1a
proteasome degradation. These results indicated that SS might be
used as an alternative treatment for cancer patients. Meanwhile,
our results also benefit future design of LDH-A inhibitors based on
EGC structure. Meanwhile, more in-depth in vitro and in vivo
studies are further required to look into the synergistic effects of
EGC with traditional chemotherapy or radiotherapy.
Supporting Information
Figure S1 Bioactivity-guided screening of SS targeting
on LDH-A. (A) First round screening. The aqueous extracts (AE),
60% ethanol extracts (ET) and fractions extracted by petroleum
ether (PE), ethyl acetate (EtOAc), n-butanol (BUOH) and water
residues (RE) of SS were subjected to screening assays including
LDH-A activity, apoptosis and LDH-A expression. The results
indicated that the EtOAc fractions of SS exhibited the highest
inhibitory ratio on LDH-A activity and expression, accompanying
with the highest apoptosis ratio; (B) 12 subfractions from EtOAc
fractions were subjected into the second round screening. The
results showed that the subfraction 4 possess the highest activity in
inhibiting LDH-A activity, expression and inducing apoptosis; (C)
Among the four compounds purified from subfraction 4, EGC
showed the highest apoptosis-induction and LDH-A inhibitory
effects.(All values represents as Mean6 SD, n= 3, *P,0.05 vs.
control).
(TIF)
Acknowledgments
The authors are grateful to the support of professors Guan Xinyuan and
HSIAO Wenluan. The authors would like to express thanks to Ms Chen
Leilei, Mr. Keith Wong, Ms Cindy lee and Mr. Freddy Tsang for their
technical support.
Author Contributions
Conceived and designed the experiments: ZW JC. Performed the
experiments: DW NW SH. Analyzed the data: WZY. Contributed
reagents/materials/analysis tools: TYL JS HH FM. Wrote the paper: ZW.
References
1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell
144: 646–674.
2. Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window
opens. Nat Rev Drug Discov 10: 671–684.
3. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism.
Nat Rev Cancer 11:85–95.
4. Warburg O (1956) On the origin of cancer cells. Science 123: 309–314.
5. Pelicano H, Martin DS, Xu RH, Huang P (2006) Glycolysis inhibition for
anticancer treatment. Oncogene 25: 4633–4646.
6. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat
Rev Cancer 4:891–899.
7. Hirschhaeuser F, Sattler UG, Mueller-Klieser W (2011) Lactate: a metabolic key
player in cancer. Cancer Res 71:6921–6925.
8. Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by
aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem
277: 23111–23115.
9. Gordan JD, Thompson CB, Simon MC (2007) HIF and c-Myc: sibling rivals for
control of cancer cell metabolism and proliferation. Cancer Cell 12:108–113.
10. Gatenby RA, Gillies RJ (2007) Glycolysis in cancer: a potential target for
therapy. Int J Biochem Cell Biol 39: 1358–1366.
11. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, et al.
(2010) Evidence for an alternative glycolytic pathway in rapidly proliferating
cells. 2010; 329: 1492–1499.
12. Shi HS, Li D, Zhang J, Wang YS, Yang L, et al. (2010) Silencing of pkm2
increases the efficacy of docetaxel in human lung cancer xenografts in mice.
Cancer Sci 101: 1447–1453.
13. Kolev Y, Uetake H, Takagi Y, Sugihara K (2008) Lactate dehydrogenase-5
(LDH-5) expression in human gastric cancer: association with hypoxia- inducible
factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis.
Ann Surg Oncol 15: 2336–2344.
14. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, et al. (2009) LDH-A
inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and
renal cell cancer. Mol Cancer Ther 8: 626–635.
15. Wang ZY, Loo TY, Shen JG, Wang N, Wang DM, et al. (2012) LDH-A
silencing suppresses breast cancer tumorigenicity through induction of oxidative
stress mediated mitochondrial pathway apoptosis. Breast Cancer Res Treat
131:791–800.
16. Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression
uncovers a link between glycolysis, mitochondrial physiology, and tumor
maintenance. Cancer Cell 9: 425–434.
17. Takahashi Y, Miyajima H, Kaneko E (1995) Genetic analysis of a family of
lactate dehydrogenase A subunit deficiency. Intern Med 34:326–329.
18. Granchi C, Bertini S, Macchia M, Minutolo F (2010) Inhibitors of lactate
dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 17:
672–697.
19. Wang Z, Wang N, Chen J, Shen J (2012) Emerging glycolysis targeting and drug
discovery from Chinese medicine in cancer therapy. Evid Based Complement
Alternat Med 2012: 873175
20. Yang DM (2003) Applaction of Spatholobus suberectus in treating leucopenia
caused by radiotherapy. Journal of Traditional Chinese Medicine 44: 730.
21. Chen DH, Luo X, Yu MY, Zhao YQ, Cheng YF, et al. (2004) Effect of
Spatholobus suberectus on the bone marrow cells and related cytokines of mice.
Zhongguo Zhong Yao Za Zhi 29:352–355.
22. Wang ZY, Wang DM, Loo TY, Cheng Y, Chen LL, et al. (2011) Spatholobus
suberectus inhibits cancer cell growth by inducing apoptosis and arresting cell
cycle at G2/M checkpoint. J Ethnopharmacol 133:751–758.
23. Cheng XL, Wan JY, Li P, Qi LW (2011) Ultrasonic/microwave assisted
extraction and diagnostic ion filtering strategy by liquid chromatography-
quadrupole time-of-flight mass spectrometry for rapid characterization of
flavonoids in Spatholobus suberectus. J Chromatogr A 1218:5774–5786.
24. Yoon JS, Sung SH, Park JH, Kim YC (2004) Flavonoids from Spatholobus
suberectus. Arch Pharm Res 27:589–592.
SS Inhibiting Breast Cancer via LDH-A
PLOS ONE | www.plosone.org 11 February 2013 | Volume 8 | Issue 2 | e56631
25. Clark AS, West K, Streicher S, Dennis PA (2002) Constitutive and inducible Akt
activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in
breast cancer cells. Mol Cancer Ther 1:707–717.
26. Minet E, Mottet D, Michel G, Roland I, Raes M, et al. (1999) Hypoxia-induced
activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 460: 251–
256.
27. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, et al. (2002) Hsp90
regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-
degradative pathway. J Biol Chem 277:29936–29944.
28. Brentani MM, Nagai MA (1983) Lactate dehydrogenase in breast carcinoma:
correlation with estrogen and progesterone receptors. Cancer Detect Prev
6:241–247.
29. Burke RE, Harris SC, McGuire WL (1978) Lactate dehydrogenase in estrogen-
responsive human breast cancer cells. Cancer Res 38:2773–2776.
30. Ocana A, Pandiella A, Siu LL, Tannock IF (2010) Preclinical development of
molecular-targeted agents for cancer. Nat Rev Clin Oncol 8: 200–209.
31. Guo W, Kong E, Meydani M (2009) Dietary polyphenols, inflammation, and
cancer. Nutr Cancer 61:807–810.
32. Gu L, Kelm MA, Hammerstone JF, Beecher G, Holden J, et al. (2003)
Screening of foods containing proanthocyanidins and their structural charac-
terization using LC-MS/MS and thiolytic degradation. J Agric Food Chem
51:7513–7521.
33. Kuzuhara T, Suganuma M, Fujiki H (2008) Green tea catechin as a chemical
chaperone in cancer prevention. Cancer Lett 261: 12–20.
34. Yang CS, Wang X, Lu G, Picinich SC (2009) Cancer prevention by tea: animal
studies, molecular mechanisms and human relevance. Nat Rev Cancer 9: 429–
439.
35. Vergote D, Cren-Olive´ C, Chopin V, Toillon RA, Rolando C, et al. (2002) (-)-
Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer
cells but not of their normal counterparts. Breast Cancer Res Treat 76: 195–201.
36. Kushima Y, Iida K, Nagaoka Y, Kawaratani Y, Shirahama T, et al. (2009)
Inhibitory effect of (-)-epigallocatechin and (-)-epigallocatechin gallate against
heregulin beta1-induced migration/invasion of the MCF-7 breast carcinoma cell
line. Biol Pharm Bull 32: 899–904.
37. Liu YV, Semenza GL (2007) RACK1 vs. HSP90: competition for HIF-1 alpha
degradation vs. stabilization. Cell Cycle 6:656–659.
38. Minet E, Mottet D, Michel G, Roland I, Raes M, et al. (1999) Hypoxia-induced
activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 460: 251–
256.
39. Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism.
Curr Opin Genet Dev 20: 51–56.
SS Inhibiting Breast Cancer via LDH-A
PLOS ONE | www.plosone.org 12 February 2013 | Volume 8 | Issue 2 | e56631
